GW rises as Epidiolex passes second Phase III test

GW Pharmaceuticals plc (LSE:GWP; NASDAQ:GWPH) said anticonvulsive therapy Epidiolex cannabidiol significantly reduced the monthly frequency of drop seizures in patients with Lennox-Gastaut syndrome (LGS), meeting the primary endpoint of a Phase III study. GW gained 60.50p (12%) to 566.50p in London on Monday, and rose $5.18 to $88.49 on NASDAQ.

Dosed as an adjunct therapy alongside anti-epileptic regimens, 20 mg/kg per day of Epidiolex reduced the monthly frequency of drop seizures by 44% during the study's 14-week treatment period vs. 22% for placebo (p=0.0135). The 171-patient trial enrolled patients aged 2-55 whose disease was uncontrolled on at least one anti-epileptic drug. Their median monthly drop seizure frequency was 74 at baseline. ...